Risk factors and clinical impact of COVID-19- associated pulmonary aspergillosis: multicenter retrospective cohort study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The risk factors and clinical impacts of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) remain controversial, and no data have been reported in Korea. This study aimed to investigate the epidemiology and importance of CAPA diagnostic efforts and to identify the predictors of CAPA and the impacts on clinical outcomes. Methods: Between January 2020 and May 2021, data of severely to critically ill COVID-19 patients were extracted from seven hospitals of the Catholic Medical Center through a clinical data warehouse. Corticosteroid use was subcategorized into total cumulative dose, early 7-day dose, mean daily dose, and duration of use. Results: A total of 2,427 patients were screened, and 218 patients were included. CAPA was diagnosed in 4.6% (10/218) of all hospitalized and 11.2% (10/89) of intensive care unit patients. Total cumulative dose (over 1,000 mg as methylprednisolone) and daily high-dose corticosteroid use (over 60 mg/day) were independent predictors but not early 7-day high-dose corticosteroid use (over 420 mg/week) (odds ratio [OR], 1.731; 95% confidence interval [CI], 0.350 to 8.571) nor prolonged use (OR, 2.794; 95% CI, 0.635 to 13.928). In-hospital overall mortality was 11.9% (26 of 218). CAPA itself did not affect the outcome; rather, daily high-dose steroid use significantly increased the 30-day mortality (hazard ratio, 5.645; 95% CI, 1.225 to 26.091). Conclusions: CAPA was not uncommon, especially in critically ill patients. Daily high-dose corticosteroid use was the predictor of CAPA and associated with high mortality rates. High-dose corticosteroids use after early inflammatory phase should be avoided, and active surveillance methods for CAPA are essential for those high-risk patients.
Abstract
Background/Aims: The risk factors and clinical impacts of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) remain controversial, and no data have been reported in Korea. This study aimed to investigate the epidemiology and importance of CAPA diagnostic efforts and to identify the predictors of CAPA and the impacts on clinical outcomes. Methods: Between January 2020 and May 2021, data of severely to critically ill COVID-19 patients were extracted from seven hospitals of the Catholic Medical Center through a clinical data warehouse. Corticosteroid use was subcategorized into total cumulative dose, early 7-day dose, mean daily dose, and duration of use. Results: A total of 2,427 patients were screened, and 218 patients were included. CAPA was diagnosed in 4.6% (10/218) of all hospitalized and 11.2% (10/89) of intensive care unit patients. Total cumulative dose (over 1,000 mg as methylprednisolone) and daily high-dose corticosteroid use (over 60 mg/day) were independent predictors but not early 7-day high-dose corticosteroid use (over 420 mg/week) (odds ratio [OR], 1.731; 95% confidence interval [CI], 0.350 to 8.571) nor prolonged use (OR, 2.794; 95% CI, 0.635 to 13.928). In-hospital overall mortality was 11.9% (26 of 218). CAPA itself did not affect the outcome; rather, daily high-dose steroid use significantly increased the 30-day mortality (hazard ratio, 5.645; 95% CI, 1.225 to 26.091). Conclusions: CAPA was not uncommon, especially in critically ill patients. Daily high-dose corticosteroid use was the predictor of CAPA and associated with high mortality rates. High-dose corticosteroids use after early inflammatory phase should be avoided, and active surveillance methods for CAPA are essential for those high-risk patients.
참고문헌 (38)
- Mi Young Ahn, "Four cases of coronavirus disease 2019 in the early stage of pandemic of South Korea: a single public hospital experience", The Korean Journal of Internal Medicine, 35(4), pp.788~792 (2020), 대한내과학회[DOI]
- Ji Young Park, "Changes in respiratory virus infection trends during the COVID-19 pandemic in South Korea: the effectiveness of public health measures", The Korean Journal of Internal Medicine, 36(5), pp.1157~1168 (2021), 대한내과학회[DOI]
- "WHO coronavirus disease (COVID-19) dashboard" (2022)[URL]
- Lansbury L, "Co-infections in people with COVID-19 : a systematic review and meta-analysis", J Infect, 81, pp.266~275 (2020)
- Machado M, "Invasive pulmonary aspergillosis in the COVID-19 era : an expected new entity", Mycoses, 64, pp.132~143 (2021)
- Lahmer T, "Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19pneumonia : results from the prospective AspCOVID-19 study", PLoS One, 16, pp.e0238825~ (2021)
- Mitaka H, "Incidence and mortality of COVID-19-associated pulmonary aspergillosis : a systematic review and meta-analysis", Mycoses, 64, pp.993~1001 (2021)
- Chong WH, "Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis(CAPA) : a systematic review and meta-analysis", Infection, 50, pp.43~56 (2022)
- Blot SI, "A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients", Am J Respir Crit Care Med, 186, pp.56~64 (2012)
- Salmanton-Garcia J, "COVID-19-associated pulmonary aspergillosis, March-August 2020", Emerg Infect Dis, 27, pp.1077~1086 (2021)
- Alanio A, "Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19", Lancet Respir Med, 8, pp.e48~e49 (2020)
- Pasquier G, "A review of significance of Aspergillus detection in airways of ICU COVID-19 patients", Mycoses, 64, pp.980~988 (2021)
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with COVID-19", N Engl J Med, 384, pp.693~704 (2021)
- Kim Sun Bean, "Revised Korean Society of Infectious Diseases", National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19, 2021, pp.53(1), 166~219[DOI]
- Park SJ, "Machine learning prediction of dropping out of outpatients with alcohol use disorders", PLoS One, 16, pp.e0255626~ (2021)
- Koehler P, "Defining and managing COVID-19-associated pulmonary aspergillosis : the 2020 ECMM", ISHAM consensus criteria for research and clinical guidance, 2021, pp.21, e149~e162
- "Clinical spectrum of SARS-CoV-2infection" (2021)[URL]
- Salton F, "Prolonged lowdose methylprednisolone in patients with severe COVID-19pneumonia", Open Forum Infect Dis, 7, pp.ofaa421~ (2020)
- COVID STEROID 2 Trial Group, "Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia : the COVID STEROID 2 randomized trial", JAMA, 326, pp.1807~1817 (2021)
- Garcia-Vidal C, "Environmental variables associated with an increased risk of invasive aspergillosis", Clin Microbiol Infect, 20, pp.O939~O945 (2014)
- Verweij PE, "Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition : an expert opinion", Intensive Care Med, 46, pp.1524~1535 (2020)
- Marr KA, "Aspergillosis complicating severe coronavirus disease", Emerg Infect Dis, 27, pp.18~25 (2021)
- Montrucchio G, "Risk factors for invasive aspergillosis in ICU patients with COVID-19 : current insights and new key elements", Ann Intensive Care, 11, pp.136~ (2021)
- Rodrigues ML, "Searching for a change : the need for increased support for public health and research on fungal diseases", PLoS Negl Trop Dis, 12, pp.e0006479~ (2018)
- Verweij PE, "Influenza coinfection : be(a)ware of invasive aspergillosis", Clin Infect Dis, 70, pp.349~350 (2020)
- Rijnders B, "Influenza-associated pulmonary aspergillosis : a local or global lethal combination?", Clin Infect Dis, 71, pp.1764~1767 (2020)
- White PL, "A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit", Clin Infect Dis, 73, pp.e1634~e1644 (2021)
- Lahmer T, "Comparison of 1, 3-β-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients", J Crit Care, 36, pp.259~264 (2016)
- Rutsaert L, "COVID-19-associated invasive pulmonary aspergillosis", Ann Intensive Care, 10, pp.71~ (2020)
- Kim Sun Bean, "Korean Society of Infectious Diseases", National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19, 2021, pp.53(2), 395~403[DOI]
- Razzack Aminah Abdul, "A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients", Infection and Chemotherapy, 53(3), pp.512~518 (2021), 대한감염학회[DOI]
- Bartoletti M, "Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19 : a prospective study", Clin Infect Dis, 73, pp.e3606~e3614 (2021)
- Tomazini BM, "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : The CoDEX Randomized Clinical Trial", JAMA, 324, pp.1307~1316 (2020)
- Manoj Kumar Reddy Somagutta, "The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis", Infection and Chemotherapy, 53(2), pp.221~237 (2021), 대한감염학회[DOI]
- Schauwvlieghe A, "Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza : a retrospective cohort study", Lancet Respir Med, 6, pp.782~792 (2018)
- Hoang Tung, "Comparison of Comorbidities in Relation to Critical Conditions among Coronavirus Disease 2019 Patients: A Network Meta-Analysis", Infection and Chemotherapy, 53(1), pp.13~28 (2021), 대한감염학회[DOI]
- 강승지, "Age-Related Morbidity and Mortality among Patients with COVID-19", Infection and Chemotherapy, 52(2), pp.154~164 (2020), 대한감염학회[DOI]
- 이현우, "Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients", The Korean Journal of Internal Medicine, 36(1), pp.1~10 (2021), 대한내과학회[DOI]